Telemedicine Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acusphere
Acusphere reports loss of $0.84 per share
September 13th, 2006
Acusphere, Inc., (ACUS) reported financial results for the quarter ended June 30, 2006 and commented on operational progress. During the 3 months ended June 30, 2006, the company's primary focus remained on its lead product candidate, AI-700, an ultrasound contrast agent being developed for use in echocardiography. The majority of operating expenses were related to the development program for AI-700 which is in phase III clinical trials designed to demonstrate that ultrasound with AI-700 is non-inferior to nuclear stress tests for the assessment of coronary heart disease, the leading cause of death in the United States. In June 2006, the company...
Source: Telemedicine Business Week (2006-09-13)
|
